Clinical Trial Update: A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of alectinib in ALK-rearranged non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED